Economic Modeling
Aventine develops evidence-based, transparent, pharmacoeconomic models for US payers, focusing on budget impact and cost-effectiveness analyses.

There is growing recognition that a comprehensive economic assessment of a new health-care intervention requires both a cost-effectiveness analysis and a budget impact analysis.1,2 In fact, many US payers are requesting both analyses when a product is submitted for coverage determination.2-4
Aventine develops evidence-based, transparent, pharmacoeconomic models for US payers, frequently in tandem with dossier development. Aventine has developed economic models across a wide range of products and disease states.
Aventine models are developed and delivered in Microsoft Excel®. Microsoft Visual Basic® is used to generate macros and control features as required. All calculations are presented such that our models provide complete transparency. Aventine-developed models are always interactive, allowing users to most closely simulate their member population’s characteristics, utilization, and costs.
Aventine Therapeutic Experience by Economic Modeling Type
Budget Impact Analyses | Cost-Effectiveness or Cost-Minimization Analyses |
---|---|
|
|
Budget Impact Models
The purpose of a budget impact model is to estimate the financial consequences of adoption and diffusion of a new healthcare intervention within the context of a specific healthcare setting or system given inevitable resource constraints.1,2 However, budget impact models are not intended to establish the overall value of a product because they do not include the full impact of the product on clinical and patient outcomes.4 Therefore, they are useful for estimating the impact on the pharmacy and/or medical budgets (eg, its affordability) and are frequently used by managed care payers.4
Cost-effectiveness Analyses
The purpose of a cost-effectiveness analysis is to assess the overall clinical risk-benefit and economic value of a product in relation to products in the class and other healthcare interventions in general; it estimates the product’s economic efficiency.2,4
References
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. Jan-Feb 2014;17(1):5-14.
- Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices–budget impact analysis. Value Health. Sep-Oct 2007;10(5):336-347.
- WellPoint. Health Technology Assessment Guidelines: Drug submission guidelines for new products, new indications, and new formulations. 2008.
- FMCP Format Executive Committee. The AMCP Format for Formulary Submissions: Version 3.1. December 2012.